IVRO Stock Overview

Develops test kits for non-animal testing applications in the United States and internationally. More details

IVRO fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 53% below our estimate of its fair value

Earnings grew by 6770.8% over the past year

Risk Analysis

Does not have a meaningful market cap ($2M)

Earnings have declined by 1.9% per year over past 5 years

Makes less than USD$1m in revenue ($811K)

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

InVitro International, Inc. Competitors

Meihua International Medical Technologies

NasdaqGM:MHUA

US$8.3m

Utah Medical Products

NasdaqGS:UTMD

US$212.9m

Medical Care Technologies

OTCPK:MDCE

US$2.4m

OraSure Technologies

NasdaqGS:OSUR

US$292.4m

Price History & Performance

Summary of share price highs, lows and changes for InVitro International
Historical stock prices
Current Share Price	US$0.11
52 Week High	US$0.13
52 Week Low	US$0.025
Beta	-1.03
1 Month Change	7.44%
3 Month Change	9.00%
1 Year Change	81.67%
3 Year Change	-65.94%
5 Year Change	36.25%
Change since IPO	-96.21%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IVRO	US Medical Equipment	US Market
7D	0%	4.3%	2.4%
1Y	81.7%	16.9%	25.0%

Return vs Industry: IVRO exceeded the US Medical Equipment industry which returned 16.9% over the past year.

Return vs Market: IVRO exceeded the US Market which returned 25% over the past year.

Price Volatility

Is IVRO's price volatile compared to industry and market?
IVRO volatility
IVRO Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.5%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.3%

Stable Share Price: IVRO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IVRO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1985	n/a	Rich Ulmer	www.invitrointl.com

InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company also provides customized technology services for Irritection Assay System installation and testing process, and independent testing laboratory services for irritancy and corrosivity testing requirements, as well as consultation and assistance services.

InVitro International, Inc. Fundamentals Summary

How do InVitro International's earnings and revenue compare to its market cap?
IVRO fundamental statistics
Market cap	US$2.47m
Earnings (TTM)	US$106.70k
Revenue (TTM)	US$811.29k

23.1x

P/E Ratio

3.0x

P/S Ratio

Is IVRO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVRO income statement (TTM)
Revenue	US$811.29k
Cost of Revenue	US$157.79k
Gross Profit	US$653.50k
Other Expenses	US$546.80k
Earnings	US$106.70k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.0047
Gross Margin	80.55%
Net Profit Margin	13.15%
Debt/Equity Ratio	0%

How did IVRO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/23 17:34
End of Day Share Price	2025/01/16 00:00
Earnings	2024/09/30
Annual Earnings	2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InVitro International, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution